141 related articles for article (PubMed ID: 19186672)
21. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
[TBL] [Abstract][Full Text] [Related]
22. Update on romiplostim and eltrombopag indirect comparison.
Cooper K; Matcham J; Helme K; Akehurst R
Int J Technol Assess Health Care; 2014 Jan; 30(1):129-30. PubMed ID: 24485057
[No Abstract] [Full Text] [Related]
23. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
24. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
25. Immune thrombocytopenia during childhood: new approaches to classification and management.
Buchanan GR
J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
[No Abstract] [Full Text] [Related]
26. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
[No Abstract] [Full Text] [Related]
27. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
28. Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.
Pignatti F; Flores B; Jonsson B
Am J Hematol; 2012 Oct; 87(10):943-4. PubMed ID: 22987253
[No Abstract] [Full Text] [Related]
29. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
Ruggeri M
Am J Hematol; 2012 Oct; 87(10):946-7. PubMed ID: 22847498
[No Abstract] [Full Text] [Related]
30. Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.
Meyer O; Wong RSM; Khelif A; Stankovic M; Maier J; Saleh MN; Bussel JB
Br J Haematol; 2022 Jan; 196(2):448-452. PubMed ID: 34458977
[No Abstract] [Full Text] [Related]
31. Platelet count or bleeding as the outcome in ITP trials?
Arnold DM
Am J Hematol; 2012 Oct; 87(10):945-6. PubMed ID: 22847526
[No Abstract] [Full Text] [Related]
32. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
33. TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis.
Rodeghiero F
Am J Hematol; 2012 Oct; 87(10):943. PubMed ID: 22847599
[No Abstract] [Full Text] [Related]
34. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
[No Abstract] [Full Text] [Related]
35. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
36. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
[TBL] [Abstract][Full Text] [Related]
37. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
Kurata Y
Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
[No Abstract] [Full Text] [Related]
38. Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
Fattizzo B; Pasquale R; Carpenedo M; Cantoni S; Auteri G; Gramegna D; D'Adda M; Napolitano M; Consonni D; Ruggeri M; Siragusa S; Rossi G; Vianelli N; Barcellini W
Haematologica; 2019 Oct; 104(10):e470-e473. PubMed ID: 30846501
[No Abstract] [Full Text] [Related]
39. New drugs 09, part 2.
Hussar DA
Nursing; 2009 Jun; 39(6):33-9; quiz 40. PubMed ID: 19474606
[No Abstract] [Full Text] [Related]
40. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
Wang XL; Li AM
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]